Pekin Singer Strauss Asset Management IL lessened its stake in shares of Pfizer Inc. (NYSE:PFE) by 9.7% in the 2nd quarter, Holdings Channel reports. The firm owned 60,328 shares of the biopharmaceutical company’s stock after selling 6,515 shares during the period. Pekin Singer Strauss Asset Management IL’s holdings in Pfizer were worth $2,189,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in PFE. BlackRock Inc. raised its holdings in Pfizer by 1.5% in the 1st quarter. BlackRock Inc. now owns 459,530,944 shares of the biopharmaceutical company’s stock valued at $16,308,754,000 after acquiring an additional 6,785,335 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in Pfizer by 11.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 47,174,487 shares of the biopharmaceutical company’s stock valued at $1,674,223,000 after acquiring an additional 4,998,981 shares during the last quarter. Jensen Investment Management Inc. acquired a new stake in Pfizer in the 2nd quarter valued at about $110,291,000. Robeco Institutional Asset Management B.V. raised its holdings in Pfizer by 75.3% in the 1st quarter. Robeco Institutional Asset Management B.V. now owns 7,038,854 shares of the biopharmaceutical company’s stock valued at $249,807,000 after acquiring an additional 3,024,270 shares during the last quarter. Finally, Neuberger Berman Group LLC raised its holdings in Pfizer by 17.9% in the 1st quarter. Neuberger Berman Group LLC now owns 16,056,110 shares of the biopharmaceutical company’s stock valued at $569,979,000 after acquiring an additional 2,432,694 shares during the last quarter. Hedge funds and other institutional investors own 69.05% of the company’s stock.
NYSE:PFE opened at $44.50 on Friday. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.16 and a quick ratio of 0.91. The company has a market cap of $261.93 billion, a P/E ratio of 16.79, a P/E/G ratio of 2.25 and a beta of 0.96. Pfizer Inc. has a fifty-two week low of $33.20 and a fifty-two week high of $45.81.
Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, July 31st. The biopharmaceutical company reported $0.81 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.74 by $0.07. The firm had revenue of $13.47 billion during the quarter, compared to analysts’ expectations of $13.30 billion. Pfizer had a net margin of 42.35% and a return on equity of 25.35%. The firm’s quarterly revenue was up 4.4% on a year-over-year basis. During the same quarter last year, the company posted $0.67 EPS. As a group, equities analysts forecast that Pfizer Inc. will post 2.99 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 3rd. Investors of record on Friday, November 9th will be given a dividend of $0.34 per share. The ex-dividend date is Thursday, November 8th. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.06%. Pfizer’s payout ratio is currently 51.32%.
A number of research firms have commented on PFE. Cantor Fitzgerald set a $45.00 price objective on shares of Pfizer and gave the company a “buy” rating in a report on Monday, August 27th. JPMorgan Chase & Co. reiterated a “buy” rating on shares of Pfizer in a report on Tuesday, July 31st. Goldman Sachs Group reiterated a “neutral” rating and issued a $42.00 price objective on shares of Pfizer in a report on Wednesday, August 1st. Zacks Investment Research downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a report on Monday, August 6th. Finally, Deutsche Bank set a $45.00 price target on shares of Pfizer and gave the company a “buy” rating in a research note on Tuesday, August 21st. Two investment analysts have rated the stock with a sell rating, thirteen have given a hold rating and nine have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $42.80.
In related news, VP Loretta V. Cangialosi sold 26,814 shares of the stock in a transaction that occurred on Wednesday, August 1st. The shares were sold at an average price of $40.16, for a total transaction of $1,076,850.24. Following the completion of the transaction, the vice president now owns 102,360 shares of the company’s stock, valued at approximately $4,110,777.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Frank A. Damelio sold 150,484 shares of the stock in a transaction that occurred on Wednesday, August 1st. The stock was sold at an average price of $40.00, for a total transaction of $6,019,360.00. Following the transaction, the insider now directly owns 337,391 shares of the company’s stock, valued at approximately $13,495,640. The disclosure for this sale can be found here. Insiders have sold a total of 234,096 shares of company stock valued at $9,366,617 in the last ninety days. 0.06% of the stock is currently owned by corporate insiders.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Featured Story: Earnings Per Share (EPS)
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.